Image_1_Comprehensive Characterization of Cachexia-Inducing Factors in Diffuse Large B-Cell Lymphoma Reveals a Molecular Subtype and a Prognosis-Related Signature.TIFF by Zhixing Kuang (10809975)

“…Background<p>Cachexia is defined as an involuntary decrease in body weight, which can increase the risk of death in cancer patients and reduce the quality of life. …”

Table_1_Comprehensive Characterization of Cachexia-Inducing Factors in Diffuse Large B-Cell Lymphoma Reveals a Molecular Subtype and a Prognosis-Related Signature.xls by Zhixing Kuang (10809975)

“…Background<p>Cachexia is defined as an involuntary decrease in body weight, which can increase the risk of death in cancer patients and reduce the quality of life. …”

Image_1_Comparison of first-line treatments for elderly patients with diffuse large B-cell lymphoma: A systematic review and network meta-analysis.tif by Yangyang Wang (642852)

Table_1_Comparison of first-line treatments for elderly patients with diffuse large B-cell lymphoma: A systematic review and network meta-analysis.docx by Yangyang Wang (642852)

Image_4_c-Rel Is the Pivotal NF-κB Subunit in Germinal Center Diffuse Large B-Cell Lymphoma: A LYSA Study.tif by Nathalie Faumont (7137200)

Image_2_c-Rel Is the Pivotal NF-κB Subunit in Germinal Center Diffuse Large B-Cell Lymphoma: A LYSA Study.jpeg by Nathalie Faumont (7137200)

Image_3_c-Rel Is the Pivotal NF-κB Subunit in Germinal Center Diffuse Large B-Cell Lymphoma: A LYSA Study.jpeg by Nathalie Faumont (7137200)

Decrease of muscle weakness and degeneration with mutants of UPS components. by Cécile Ribot (11944875)

Intracellular Ca²⁺ signaling and IP3R2 expression are decreased in <i>Tcirg1</i>-knockdown osteoclasts. by Dongyan Zhang (640677)

Maps of median projected λ_<i>S</i> (a) and <i>R</i>₀ (b) across 1st-level sub-national administrative regions in selected African countries. by Keith Fraser (1868587)

Results of SD-TOPSIS application ‐ combinations B1-B5. by Roman Vavrek (13200141)

Increased and decreased proteins. by Diego Iacono (10785756)

Subjects:

<i>N</i>. <i>bombycis</i> coated with Vg in the ovarioles of <i>S</i>. <i>litura</i> and <i>H</i>. <i>armigera</i>. by Chunxia Wang (766713)

Subjects:

Maps of median projected λ_<i>S</i> (a) and <i>R</i>₀ (b) across 1st-level sub-national administrative regions in selected South American countries. by Keith Fraser (1868587)

Average effect size decreased as sample size increased for all types of analyses (<i>p</i> < .001). by Luke J. Ney (12621627)

Colony count for CAN mutagenesis assay. by Thong T. Luong (13833935)

DataSheet_1_A nationwide analysis of the treatment patterns, survival, and medical costs in Korean patients with relapsed or refractory diffuse large B-cell lymphoma.docx by Jeong-Yeon Cho (11787386)

“…Background<p>Approximately one-third of patients with diffuse large B-cell lymphoma (DLBCL) are refractory to treatment or experience relapse after initial therapy. …”

Image2_Inhibition of CISD2 enhances sensitivity to doxorubicin in diffuse large B-cell lymphoma by regulating ferroptosis and ferritinophagy.JPEG by Chaofeng Zhang (845343)

“…Background<p>CDGSH iron-sulfur domain 2 (CISD2), an iron-sulfur protein with a [2Fe-2S] cluster, plays a pivotal role in the progression of various cancers, including Diffuse Large B-cell Lymphoma (DLBCL). However, the mechanisms by which CISD2 regulates the occurrence and development of DLBCL remain to be fully elucidated.…”

Image_2_Identification and Assessment of Necroptosis-Related Genes in Clinical Prognosis and Immune Cells in Diffuse Large B-Cell Lymphoma.jpeg by Qikai Zhang (6905096)

“…Background<p>With the unveiling of new mechanisms and the advent of new drugs, the prognosis of diffuse large B-cell lymphoma (DLBCL) becomes promising, but some patients still progress to the relapse or refractory stage. …”

Image_4_Identification and Assessment of Necroptosis-Related Genes in Clinical Prognosis and Immune Cells in Diffuse Large B-Cell Lymphoma.jpeg by Qikai Zhang (6905096)

“…Background<p>With the unveiling of new mechanisms and the advent of new drugs, the prognosis of diffuse large B-cell lymphoma (DLBCL) becomes promising, but some patients still progress to the relapse or refractory stage. …”